Deepika Pakianathan Sells 231,548 Shares of Karyopharm Therapeutics Inc. (NASDAQ:KPTI) Stock

Karyopharm Therapeutics Inc. (NASDAQ:KPTIGet Free Report) Director Deepika Pakianathan sold 231,548 shares of the company’s stock in a transaction that occurred on Friday, June 7th. The shares were sold at an average price of $0.95, for a total value of $219,970.60. The transaction was disclosed in a filing with the SEC, which can be accessed through this hyperlink.

Deepika Pakianathan also recently made the following trade(s):

  • On Wednesday, June 5th, Deepika Pakianathan sold 468,044 shares of Karyopharm Therapeutics stock. The stock was sold at an average price of $0.96, for a total value of $449,322.24.
  • On Monday, June 3rd, Deepika Pakianathan sold 360,744 shares of Karyopharm Therapeutics stock. The stock was sold at an average price of $1.00, for a total value of $360,744.00.
  • On Friday, May 31st, Deepika Pakianathan sold 204,394 shares of Karyopharm Therapeutics stock. The stock was sold at an average price of $0.95, for a total value of $194,174.30.

Karyopharm Therapeutics Price Performance

KPTI opened at $0.96 on Friday. The company has a market capitalization of $119.66 million, a price-to-earnings ratio of -0.76 and a beta of 0.25. Karyopharm Therapeutics Inc. has a 1-year low of $0.62 and a 1-year high of $2.42. The business has a 50 day moving average price of $1.13 and a two-hundred day moving average price of $1.08.

Karyopharm Therapeutics (NASDAQ:KPTIGet Free Report) last released its earnings results on Wednesday, May 8th. The company reported ($0.32) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.33) by $0.01. The firm had revenue of $33.13 million during the quarter, compared to analyst estimates of $35.02 million. Equities analysts expect that Karyopharm Therapeutics Inc. will post -1.25 EPS for the current fiscal year.

Institutional Investors Weigh In On Karyopharm Therapeutics

A number of institutional investors and hedge funds have recently modified their holdings of KPTI. GSA Capital Partners LLP acquired a new stake in shares of Karyopharm Therapeutics during the 3rd quarter valued at $762,000. Los Angeles Capital Management LLC acquired a new stake in shares of Karyopharm Therapeutics during the 4th quarter valued at $339,000. Panagora Asset Management Inc. acquired a new stake in shares of Karyopharm Therapeutics during the 4th quarter valued at $197,000. Monashee Investment Management LLC acquired a new stake in shares of Karyopharm Therapeutics during the 4th quarter valued at $115,000. Finally, BNP Paribas Financial Markets lifted its position in shares of Karyopharm Therapeutics by 6.5% during the 4th quarter. BNP Paribas Financial Markets now owns 1,769,184 shares of the company’s stock valued at $1,530,000 after acquiring an additional 108,286 shares during the last quarter. Institutional investors and hedge funds own 66.44% of the company’s stock.

Analysts Set New Price Targets

Separately, HC Wainwright reiterated a “buy” rating and set a $8.00 price objective on shares of Karyopharm Therapeutics in a research report on Monday, June 3rd. Three analysts have rated the stock with a hold rating and three have issued a buy rating to the stock. Based on data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and an average target price of $4.80.

View Our Latest Stock Report on Karyopharm Therapeutics

Karyopharm Therapeutics Company Profile

(Get Free Report)

Karyopharm Therapeutics Inc, a commercial-stage pharmaceutical company, discovers, develops, and commercializes drugs directed against nuclear export for the treatment of cancer and other diseases in the United States. The company discovers, develops, and commercializes novel and small molecule Selective Inhibitor of Nuclear Export (SINE) compounds that inhibit the nuclear export protein exportin 1 (XPO1).

Further Reading

Insider Buying and Selling by Quarter for Karyopharm Therapeutics (NASDAQ:KPTI)

Receive News & Ratings for Karyopharm Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Karyopharm Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.